Advanced Biomed (ADVB) vs BioNexus Gene Lab (BGLC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Advanced Biomed is the larger company by market cap ($2.7 million vs $2.0 million), about 1.4 times the size. Advanced Biomed converts more of its revenue into profit, with a net margin of 5231.3% versus -40.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADVB | BGLC |
|---|---|---|
| Share price | $1.65 | $0.68 |
| Market cap | $2.73M | $1.99M |
| 1-day change | -5.71% | 0.00% |
| YTD return | -71.75% | — |
| 1-year return | -77.76% | — |
| EPS (TTM) | $-5.03 | $-1.26 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $127.64K | $7.42M |
| Revenue growth (YoY) | — | -21.93% |
| Net income (latest FY) | $6.68M | $-2.98M |
| Gross margin | — | 14.62% |
| Operating margin | -4883.80% | -39.93% |
| Net margin | 5231.30% | -40.20% |
| 52-week high | $24.23 | $4.97 |
| 52-week low | $1.58 | $0.621 |
| Distance from 52-week high | -93.19% | -86.32% |
| Average volume | 88.38K | 6.70K |
| Shares outstanding | 1.65M | 2.93M |
| Employees | 31 | 19 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Advanced Biomed is more profitable, keeping 5231.3 cents of every revenue dollar as net income versus -40.2 cents for BioNexus Gene Lab.
About Advanced Biomed
ADVB stock →Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies for precision oncology detection, diagnosis, and treatment in Taiwan. Its devices include A+Pre, an automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cell (CTC) single-cell capture device; and A+CellScan, an analyzer with an immunostaining chip for immunostaining/analysis of the AC-1000 product.
Health Care · Medical Specialities · 31 employees
About BioNexus Gene Lab
BGLC stock →BioNexus Gene Lab Corp., together with its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding.
Health Care · Medical Specialities · 19 employees
ADVB vs BGLC FAQ
Which is bigger, Advanced Biomed or BioNexus Gene Lab?
Advanced Biomed (ADVB) is larger, with a market capitalization of $2.73M compared with $1.99M for BioNexus Gene Lab (BGLC).
Are Advanced Biomed and BioNexus Gene Lab in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.